An interventional study of Catheter ablation using sequential radiofrequency and pulsed field ablation in Ventricular Tachycardia (V-Tach), sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre. Active, not recruiting at 3 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies in Tachycardia, Ventricular with a site in Canada — 17 open to participants now, 19 under way, 2 of them phase 3. Tachycardia, Ventricular · Canada.
Among the 54 studies in Tachycardia, Ventricular with a site in Canada, this one is the 26th largest by planned enrollment of the 39 interventional ones that give a count, is one of 5 that started in 2025, is one of 19 with no phase, reaches primary completion later than 3 of the 18 other live ones, and was the 48th registered.
452 studies on the registry are indexed under Tachycardia, Ventricular; 121 are open to participants now.
Browse Tachycardia, Ventricular studies →17 of the 54 studies in Tachycardia, Ventricular with a site in Canada are open now. Recruiting first, the newest first:
Adagio Medical · Sites in Canada, United States
Ages 18+
Cardurion Pharmaceuticals, Inc. · Sites in Canada, United States, France and 3 more countries
Ages 18–99
Thermedical, Inc. · Sites in Canada, United States
Ages 18+
Ottawa Heart Institute Research Corporation · Sites in Canada
University Hospital, Basel, Switzerland · Sites in Canada, United States, Austria and 13 more countries
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 86 Tachycardia, Ventricular studies recruiting now, 67 (78%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 70 across 281 interventional studies indexed under Tachycardia, Ventricular.
Median enrollment 130 across the 39 interventional studies, 1,735 across the 15 observational. Of the 33 that completed or were terminated, 16 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 54 have an industry lead sponsor. The 10 most frequent:
McGill University Health Centre/Research Institute of the McGill University Health Centre is the lead sponsor of 422 studies on the registry; 106 are open to participants now.
McGill University Health Centre/Research Institute of the McGill University Health Centre has 2 studies filed under Tachycardia, Ventricular — fewer than ten, so there is no comparison to draw.
10 of the studies in Tachycardia, Ventricular with a site in Canada that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05047198Phase 3Ottawa Heart Institute Research CorporationCatheter Ablation Versus Radio-Ablation for Ventricular Tachycardia: a Randomized Controlled Trial | 2026-12-31 |
| NCT06281977Phase 3Ottawa Heart Institute Research CorporationStudy Evaluating Dexmedetomidine in the Acute Treatment of Electrical Storm | 2027-05-08 |
| NCT04520347University of California, Los AngelesIVTCC 2.0: A Prospective Multicenter Ventricular Tachycardia Catheter Ablation Registry | 2026-12 |
| NCT05258422McGill University Health Centre/Research Institute of the McGill University Health CentreStereotactic Arrhythmia Radioablation for Ventricular Tachycardia (StAR-VT) | 2026-12-31 |
| NCT03713866John SappPeri-Procedural Transmural Electrophysiological (EP) Imaging of Scar-Related Ventricular Tachycardia | 2026-12-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 54 studies in Tachycardia, Ventricular with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This will be a single arm study evaluating a new ablation technology for performing catheter ablation of ventricular tachycardia. The technology combines novel pulsed field ablation with radiofrequency ablation.
One of the limitations of conventional ventricular tachycardia (VT) ablation using radiofrequency (RF) energy is the inability to reach arrhythmogenic tissue deep in the myocardium. Pulsed field (PF) energy, which causes cell death via irreversible electroporation and is non-thermal, may improve outcomes in patients with VT since it has been shown to have better depth penetration in previously scarred tissue. Furthermore, the combination of RF and PF treatment in the same location can increase tissue lesion depth more than either energy alone. This can potentially minimize the need for epicardial ablations, or complex bipolar ablation strategies as well as associated procedural complications. RF and PF have been used extensively for atrial ablation. RF has been the mainstay for all VT ablation but PF use for VT is relatively new.
Pre-clinical work of ventricular ablation procedures in a swine model evaluated the effects of combined and co-localized PF and RF application on cardiac lesion size and their corresponding histological changes. Compared to PF alone ablation, lesion depths and widths were significantly greater in both RF-PF and PF-RF applications. Histology for both combined lesions showed central thermal necrosis surrounded by a hemorrhagic and transitional PF zone. The findings provided evidence for appropriate use of combination therapy in clinical settings.
The design of the study will be carried out as an interventional, prospective, multicenter, single-arm safety and effectiveness evaluation using the Biosense Webster PF/RF Ablation System. The study will enroll subjects with sustained symptomatic VT who are candidates for catheter ablation. Eligible subjects who sign the Informed Consent Form (ICF) and who meet all eligibility criteria will be enrolled and treated with the STSF Catheter in conjunction with the TRUPULSE™ Generator. A maximum sample size of 30 subjects is planned in the study. All study subjects will be followed-up for 6 months after the study procedure.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with two or more documented spontaneous episodes of sustained symptomatic VT within 3 months or 1 sustained episode of VT or VT storm (two or more VTs in 24 hours) which required device therapy (shock or anti-tachycardia pacing), external cardioversion, escalated antiarrhythmic therapy, and / or hospitalization
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients in this single arm will all undergo clinically-indicated catheter ablation of ventricular tachycardia using a novel combination ablation device capable of delivering both radiofrequency and pulsed field ablation.
Device: Catheter ablation using sequential radiofrequency and pulsed field ablation
We are using sequential application of radiofrequency and pulsed field ablation to increase lesion depth and better treat ventricular arrhythmias.
Acute procedural success (elimination of all clinically relevant ventricular tachycardias)
Elimination of all clinically relevant ventricular tachycardias at the end of the procedure.
Time frame: 6 months
Primary Safety Outcome
Primary adverse events (PAE) within 7 days after ablation
Time frame: From ablation procedure until 7 days post-ablation
Freedom from ventricular tachycardia recurrence at 6 months post-ablation
Freedom from recurrence (symptomatic or asymptomatic) of monomorphic VT that was targeted at ablation at 6 months following the ablation procedure, plus additional failure modes including acute procedural failure, repeat ablation failure, non-study device failure, AAD failure
Time frame: From ablation until 6 months post-ablation
Secondary safety outcome
Primary adverse events at 7 days - 6 months after ablation
Time frame: From 7 days until 6 months post-ablation
Quality of life using ICDC score
Quality of life using the ICDC quality of life score. There are 20 questions each ranked on a Likert scale from 0 to 4. Points are given for number of questions showing any concern and the degree of concern for a total of 100 points.
Time frame: 6 months post-ablation
Plan to share: No — All relevant data will be published at study end in final manuscript. This is a small, pilot, first-in-human study.
No publications or documents are linked to this record.
Ran from Jul 2025 to primary completion in Sep 2026, 14 months.
Of 86 non-industry interventional studies with no phase under Tachycardia, Ventricular, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 70. This study's 14 months is below that.
Counting every sponsor, half of 126 studies reached it within 36 months; a quarter within 20 and three quarters within 66.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: primary completion Jul 2026 → Sep 2026 and completion Aug 2026 → Jan 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
McGill University Health Centre/Research Institute of the McGill University Health Centre →